Literature DB >> 15599467

Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia.

Chung-Hsu Lai1, Chih-Yu Chi, Hsin-Pai Chen, Te-Li Chen, Chorng-Jang Lai, Chang-Phone Fung, Kwok-Woon Yu, Wing-Wai Wong, Cheng-Yi Liu.   

Abstract

Stenotrophomonas maltophilia is an important nosocomial pathogen with intrinsic multi-drug resistance. This retrospective study reviewed 84 episodes of S. maltophilia bacteremia over a 4-year period from July 1999 to September 2003. Stenotrophomonas maltophilia bacteremia was hospital-acquired in 64 patients (76%), and developed after prolonged hospitalization in 48 (57%). Seventy patients (83%) had a central venous catheter (CVC), 64 (76%) had prior antibiotic therapy, 55 (65%) had underlying malignancy, and 43 (51%) were receiving immunosuppressive therapy. Twenty seven percent of the episodes of bacteremia had polymicrobial isolates. The overall and bacteremia-related mortality rates were 44% and 33%, respectively. Forty six percent of the bacteremia-related mortality occurred within 3 days after onset of symptoms. The most common sources of bacteremia were respiratory tract (33%) and CVC (31%), while the source of the bacteremia was unknown in 26% of episodes. The most effective antibiotics in vitro were trimethoprim-sulfamethoxazole, ciprofloxacin, chloramphenicol, and ceftazidime; however, a trend of increasing drug resistance in these agents was identified over the study period. On univariate analysis, nosocomial bacteremia, long-lasting neutropnenia (>10 days), bacteremia originating from the respiratory tract, shock, low serum albumin level (<3 g/dL), and thrombocytopenia (platelet count <100,000/mm3) were significantly related to mortality (p<0.05). Among these variables, shock and thrombocytopenia were independent factors associated with mortality. In contrast, patients with CVC-related bacteremia had a lower mortality rate (odds ratio, 0.04; p<0.001). Patients treated with appropriate antibiotics had a lower mortality rate, but this difference was not significant (p=0.477). In S. maltophilia bacteremia, careful evaluation of CVC was important for identifying the source of bacteremia and predicting prognosis. The source of bacteremia and condition of patients at presentation were the major factors influencing prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15599467

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  46 in total

1.  Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009.

Authors:  H Araoka; M Baba; A Yoneyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-23       Impact factor: 3.267

2.  Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia.

Authors:  Gokhan Metan; Omrum Uzun
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

4.  Changing trends in etiology of bacteremia in patients with cancer.

Authors:  A Safdar; G H Rodriguez; M Balakrishnan; J J Tarrand; K V I Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

5.  Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients.

Authors:  B Saugel; K Eschermann; R Hoffmann; A Hapfelmeier; C Schultheiss; V Phillip; F Eyer; K-L Laugwitz; R M Schmid; W Huber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-07       Impact factor: 3.267

6.  External validation of bloodstream infection mortality risk score in a population-based cohort.

Authors:  M N Al-Hasan; Y J Juhn; D W Bang; H-J Yang; L M Baddour
Journal:  Clin Microbiol Infect       Date:  2014-03-26       Impact factor: 8.067

7.  Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.

Authors:  Ji-Yong Lee; Cheol-In Kang; Jae-Hoon Ko; Woo Joo Lee; Hye-Ri Seok; Ga Eun Park; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  A Systemic Lupus Erythematosus Patient With Febrile Neutropenia Developing After Intraocular Administration of Bevacizumab.

Authors:  Hamdi Sözen; Gönen Mengi; Bülent Hüddam; Selmin Çaylak; Mehmet Deveer; Volkan Karakuş; Burak Ekrem Çitil
Journal:  Arch Rheumatol       Date:  2016-01-28       Impact factor: 1.472

9.  Cluster of Stenotrophomonas maltophilia endocarditis after prosthetic valve replacement.

Authors:  Manica Müller-Premru; Tone Gabrijelcic; Borut Gersak; Jana Kolman; Natasa Svent-Kucina; Vesna Spik; Tatjana Lejko-Zupanc
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  A review of 11 years of Stenotrophomonas maltophilia blood isolates at a tertiary care institute in Canada.

Authors:  Prenilla Naidu; Stephanie Smith
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.